Protalix amends at-the-market offering agreement to reflect new S-3 registration

Protalix BioTherapeutics, Inc.

On August 22, 2025, amended Sales Agreement with H.C. Wainwright & Co., LLC.
Amendment updates the registration statement to Form S-3 (No. 333-286802).
At-the-market equity offering program terms remain unchanged.

item 1.01 item 9.01

Protalix BioTherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-081924

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.